Thank you you, Jim. Thank joining Good evening. us. for
In As rather Jim better quarter investors few the that to of we chemotherapy XXXX, than we announced of end next-generation five stated, of would our that at call our three a we which would began we be oncology drugs, drugs. the XXXX, portfolio be on our the drugs it if our realize focus of we for drugs. prioritizing development first
Slide X, please.
has mission our However, not changed.
to We are focusing options, treatment next-generation who cancer now drugs. with but no only patients on we need patients still treatment are our treat have drugs or and developing better chemotherapy
slide. oncologist It at right the drug is be schedule. goal Next of dose the patient and of the following every the treatment right every with treated desire to right the
case. to chemotherapy ago, years the that only cells. dividing, XX right and metabolites the were drugs So from for cancer keep cells making drugs often not cancer more XX this growing, is and
backbone the and drugs drugs used the discontinue chemotherapy requiring the who or side capecitabine, to and gemcitabine, drugs dose all are remain of are has cancers, to to types but the effects to treatment, their from chemotherapy of start of cancer anywhere the of XX% patient cancer These irinotecan. used now, decrease cancer widely doses patients three in therapy. Even three most suboptimal XX% treatment
so it is distributed FDA-approved because drug develop we the mechanism positive than Processa's of the of versions metabolized typically And call response. are chemotherapy have than taking We cells. less have differently that same drugs. three XX% drugs, these next for while it maintaining of killing is the altered cancer patients these to where mission those the active next-generation body a generation in is and metabolite the drug them
allows the life to chemotherapy, been in on their the to given side profile a studies effects chemotherapies severe shown less have in already potentially have versions next-generation fewer next-generation and/or cancer a more clinical exposed next-generation side effect and to may An when and quality patient be These animal even improvement effects. cancer-killing of better side molecules. have with
thus patients rate versions what are are respond than I'm question each our asking yourselves to The providing that you more these is they next-generation it than sure of used chemotherapy, response drugs. next-generation would addition, better is of drugs, drugs? many why of presently the existing are these greater likely In and a chemotherapy that
let's this, Slide answer To X. -- look little Number a bit
new oncology-oriented existing developing the at look for majority or cancer are treatments targets you new many developing drug a for delivery If an system companies, the drug. vast
in into cancer-killing metabolites metabolites the metabolized then when that body, active and drugs, that If see left, will you administered, to may the look to picture chemotherapy you on first at absorbed are effects. the normal cells out then also cells. eliminated cells, killing the they are and side cancer And distributed are cause They but side body. to effects cells, causing of cancer the normal
and take handles the widely and altering chemotherapy What used body distributed capecitabine, or in metabolizes next-generation irinotecan, drugs the the Processa three body done treatments, has to showed them, body specifically how the these chemotherapy gemcitabine, all how is drugs. how the are
order changed We the have the handled administering to mechanism however, altered metabolism either an second approved changed cancer we drug drug metabolism in changed them only that the by we in cancer not the or a of the or have body is the and distribution drug molecular have The the change structure the We slightly cells. with key, before the the the distribution, by alters drug. that the is how killing how cancer drug of of body cells. kills drug
patients And are their Next are be drug, quality next-generation and would potentially each slide. treated. be who more than less XXX,XXX of our effects there patients diagnosed increase is their survival those better next-generation life. of cancer groundbreaking cancer receiving targeted each could chemotherapy with side both The to aspect treatment that that for with and efficacy drug
-- our products development. you bottom from As bottom the the a perspective, efficient chemotherapy corporate helps in pipeline from and development, be drugs to more of in these approval, at existing investor our products differentiates can products us slide, the drug in probability of presently see increases having next-generation FDA and and the
companies. Next two last approach by regulatory the also of founders. drug it's drugs. been of refined from slide. the not years our approval has and we approach how development the other It's Processa these the use Processa We differentiate that assets FDA that XX science just over But us
principles and the initiative more has FDA requesting addition, the be oncology been guidance. draft oncology recently, science regulatory used Optimus the FDA of that In related FDA Project the under
that requires principles every for the summons. proposed regimen Optimus using justified and the This NDA dosage be oncology label regulatory and of Project submission, the must
science for Project Optimus approach Project and of drugs. to principles our other regulatory prior next-generation by for of FDA the within drug the approvals used non-oncology a we've Optimus announcement use the FDA our started have number approach already the us, to for Fortunately,
clinical to clinical design. experienced with not fact oncology the Project trials other their hand, and having regimens principles many study dosing On additional Optimus to are pivotal and in companies are justify other the of conduct
The combination more of and our of non-oncology develop Project of principles submissions FDA are next-generation includes our of the of Optimus, experience Optimus reasons efficiently chemotherapy the more regulatory we science with Project approach the our in that pipeline drugs, principles why can already next-generation each drugs.
NGC of We existing differentiate counterpart can from have approval, probability its and better a therapy. each we obtaining
slide. Next
discuss now months. the six over of drugs results two three of the me last next-generation Let our to some and
Cumulatively, cancers, per gastric, First, many looking have cancers these of new patients breast, of and to prodrug year. an colorectal, rate in XXX,XXX is other X-FU used oral and pancreatic, you, capecitabine the greater cancers. capecitabine, remind widely at next-generation of is incident types including than
PCSXXXX, the capecitabine combination itself. which alters distribution Next-generation and metabolism of capecitabine and treatment is capecitabine
data a of to capecitabine slide. few trial. I slide. Xb on Next is the point This next-generation date our slide items summary from a out to the would clinical Phase like
next-generation metabolism that the of distribution capecitabine. found we First, alters capecitabine
so This Second, of of the at XX% events called since patients doses important capecitabine from does catabolites. table, in all adverse present XX% events cause is evaluated next-generation have the capecitabine to adverse metabolite last catabolites any the not from the the to column note, far receiving
toxicities, FDA regimens efficacy and identified Xb will exposure be we level in mid-April as that have which dose-limiting do Project abbreviated we and exposure Phase should with to Fourth, DLT. meeting of drug levels cause Optimus. that discuss or exposure DLT, our cause used be not Third, levels implementation safety trial the
our goal enrollment complete is performance lastly, analysis the Xb of And of Phase XXXX. second XXXX, the and half trial interim mid-XXXX, in by to end initiate the
irinotecan drug. let's Now at our look next-generation
who year cancers than of Next per are more irinotecan diagnosed patients XXX,XXX slide. there for. that types the Again, is with used are
wanted by slide. other to drug. a versus do dose was need Optimus? Optimus Project FDA-approvable for as Project study dose response evaluating we clinical words, recommended to dose-ranging an determine do Next important this In determine We if to
irinotecan animal are irinotecan we have for What from models analyzed response the different. our is exposure that next-generation and cancer relationships
which decrease, Looking at MTD line. MTD events tolerated for of dose or efficacy, blue is the dose is irinotecan, But red maximum the the left the remains the the from decrease which the same. XX% about figure, if the next-generation the we line, to adverse the
to both irinotecan, the in the results MTD the however, decrease figure events adverse in For the and the on the XX% decreasing dose efficacy. a of in right,
concluded for relationships, which next-generation principles used besides Optimus adverse We not do requirement approval exposure appear now next-generation to FDA for irinotecan an dosage path follow of to because that oncology event being parallel a and need their irinotecan. evaluate the of regimen Project drugs, be needs justification the exposure the to for for the efficacy
last of and slides, This accomplish have what to what slide Next in to describes overview we've like plan three the XXXX. XXXX. provide I XXXX we accomplished slide. In would an in accomplished briefly what in we
next-generation accomplishments key drugs. three to in XXXX point briefly our for just me Let
First, what levels will side next-generation levels not. what we exposure and effects dose-limiting would drug determined capecitabine exposure cause
follow defined and Second, pattern. exposure event And similar gemcitabine. next-generation Xb-targeted the efficacy that exposure have third, we for irinotecan next-generation the relationships populations determined not cancer do adverse have we
rate larger drugs, we positive in non-oncology improving gastroparesis or gastric a our effect placebo emptying Phase Xa on partner, completed we've XXXXX a to For effect had and in which hope XXXXX gastroparesis find symptoms. which the [outlicense] trial a and
different for which to we XXX, from to due starting published difficulties, study. And the the prior enrollment discontinued trial the is literature
evaluating future licensees other indications are with for partners. populations now or larger We
of at to end FDA we expect slide. with we goal Xb XXXX XXXX The understanding sites steps; adverse capecitabine, safety Xb enrollment meet in with For major we exposure the the to in initiate with and -- expect mid-XXXX Phase and lastly, efficacy to XXXX, next-development the we our to Phase Xb hope milestones mid-April are: interim analysis analysis to discuss achieve relationship; and Next expect interim complete our refine study to next-generation trial Phase XXXX. trial event complete in the have in the of to the
to and of Phase efficacy next-generation IND a and next submit fourth initiate development trial the to For mid-XXXX trial to the in the meet FDA XXXX safety steps gemcitabine, with in quarter expect XXXX. the with goal in on protocol Phase we the Xb Xb
in the initiate goal hope by IND-enabling we studies to XXXX studies to irinotecan, complete XXXX. end the next-generation For of the with
partnering drugs. now are non-oncology we also or licensing our or consider drugs, more of licensing would our or But next-generation chemotherapy one drugs. Regarding monetizing we working on our partnering
expanding media, social are investors. group to our we by visibility Corporately, public engaging with as well planning our IR/PR more communicate including an and presence, as
We and opinion also leaders including oncology community, advocacy key plan to interact groups. the more patient with
last slide This the the slide. slides. Next some material previous summarizes of in
questions we earnings investors. my we end the received call, I a Before would from that part few of thought I address
The chemotherapy new finding is instead next-generation of address treatment? why I'd first develop one we've to like asked, been a oncology
These presently -- because differently, should they they their by will profile provide handled effects. slides, and because are the life. way and they our chemotherapy As But better when of new not drugs next-generation improve for it better drugs. that are I same the kill a less the a They new stated in approval. the as drugs benefit quality side represent cancer the treatment risk new for are patients cancer provide survival discussing approved body
drugs implementation drugs. be drugs have these including these better developed, greater than and Optimus, regulatory of chemotherapy principles options of the efficiently probability With the treatment approach, Project approval, will of FDA-approved be the our a more science existing next-generation and can
These are shareholder implemented number presence have media. included of by the question and are our increase process to improve we is to bringing number second steps value? shareholder enhance everything group you the Processa of what A from our IR/PR to taking in our on of launching more. we increasing value, to visibility the to that presentations asked been strategies We've quality have website social -- on and increase include a
And make oncology the hopefully with we that to and physicians to out as make as to I development expedite chemotherapy process reaching and said, possible. are known. our finally, more also as Processa are and drugs working both sure We're community, patients, next-generation better development the FDA efficient
-- and the any purchased blacked of year Hopefully, quarter C-suite Unfortunately, near is this the Some the members that Board -- the all have million during most the The future. been C-suite has well, which raise address last question shares not last earlier XXXX, of in were asked, in stock change of recently? like I'd of why $X we've to not involved Jim first Processa have out, that the been impossible. of made mentioned. we type purchase will
keenly close our by are my and of that I of want saying recent to management team in underperformance I stock the aware months.
As play all involved. of this remains an us noted for earlier, equity
create we we with best collective things on Processa for our believe displeased While are have and investors. valuation, are those our its the focused in doing which and to value interest current potential substantial all
to you. I'd to Operator, like it hand
